

Supplemental Table S2. Risk of All Clinical Fractures or Vertebral Fractures according to the Timing of Subsequent Denosumab Injections in Subjects without Any Previous History of Fractures

Variable	Subsequent denosumab inject time				
	150–180 days (ED30)	181–210 days (Reference)	211–270 days (DD90)	271–360 days (DD180)	361 days or more (DD181+)
Cases	16,761	96,844	12,786	5,085	5,545
All clinical fractures					
Fracture	153	827	123	59	41
Case-year	8,345	48,138	6,161	2,030	1,531
Incidence, /100 case-yr	1.83 (1.55–2.15)	1.72 (1.60–1.84)	2.00 (1.66–2.38)	2.91 (2.21–3.75)	2.68 (1.92–3.63)
HR	1.07 (0.90–1.27)	Reference	1.16 (0.96–1.40)	1.68 (1.29–2.19)	1.53 (1.12–2.10)
<i>P</i> value	0.46		0.002	<0.001	<0.001
Vertebral fractures					
Fracture	81	424	66	33	30
Case-year	8,363	48,242	6,175	2,036	1,533
Incidence, /100 case-yr	0.97 (0.77–1.20)	0.88 (0.80–0.97)	1.07 (0.83–1.36)	1.62 (1.12–2.28)	1.96 (1.32–2.79)
HR	1.10 (0.87–1.40)	Reference	1.22 (0.94–1.58)	1.83 (1.28–2.61)	2.18 (1.51–3.16)
<i>P</i> value	0		0.14	0.001	<0.001

ED, early dosing; DD, delayed dosing; HR, hazard ratio.